Evidence map›Paper›PMID 29371871›Full record

ArticleARYA atherosclerosis2017

Effect of crocin, a carotenoid from saffron, on plasma cholesteryl ester transfer protein and lipid profile in subjects with metabolic syndrome: A double blind randomized clinical trial.

Ali Javandoost, Asma Afshari, Irandokht Nikbakht-Jam, Mohammad Khademi, Saied Eslami, Mina Nosrati, Mojtaba Foroutan-Tanha, Amirhossein Sahebkar, Shima Tavalaie, Majid Ghayour-Mobarhan and 4 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in ARYA atherosclerosis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 5 pooled it
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 5 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Impact ofNutrients · 2020
    Pooled it
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Potential therapeutic effects of crocin.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  13. Saffron (Nutrients · 2024
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Ali JavandoostMetabolic Syndrome Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Asma AfshariAssistant Professor, Department of Nutrition, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Irandokht Nikbakht-JamMetabolic Syndrome Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad KhademiPhD Candidate, Student Research Committee, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Saied EslamiProfessor, Pharmaceutical Research Center AND School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Mina NosratiMetabolic Syndrome Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mojtaba Foroutan-TanhaMetabolic Syndrome Research Center AND Cardiovascular Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Amirhossein SahebkarAssociate Professor, Department of Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Shima TavalaieMetabolic Syndrome Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid Ghayour-MobarhanProfessor, Cardiovascular Research Center AND Metabolic Syndrome Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Gordon FernsSchool of Brighton and Sussex Medical, Division of Medical Education, Mayfield House, University of Brighton, Brighton, UK.
Farzin HadizadehProfessor, Biotechnology Research Center AND School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Abolghasem TabassiPharmacological Research Center of Medicinal Plants AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ahmad MohajeriAssociate Professor, Pharmacological Research Center of Medicinal Plants, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mashhad University of Medical Sciences · IRBrighton and Sussex Medical School · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic syndrome is defined by insulin resistance and a clustering of other cardiovascular risk factors. Crocin is a carotenoid derived from the stigmas of the saffron flower and had previously been shown to affect lipid profile. However, the mechanism for this function is not well understood. The present trial aimed to investigate the possible effect of crocin on plasma levels of cholesteryl ester transfer protein and lipid profile in individuals with metabolic syndrome.

methodsThis was a randomized, double-blind, placebo-controlled, clinical trial consisting of an 8-week treatment with crocin, or placebo tablets between April and June 2014, in the Nutrition Clinic of Ghaem Teaching Hospital, Mashhad, Iran. Participants were randomly assigned to take a 30 mg/day crocin (n = 22) in the intervention group or placebo (n = 22) in the control group. Anthropometric, hematological and biochemical parameters were measured and recorded during pre and post-treatment periods.

resultsWhilst plasma cholesteryl ester transfer protein was increased in the group taking the crocin tablet by 27.81% during the trial period (P = 0.013), the difference between the crocin and placebo groups was not significant (P = 0.116). Moreover, the percent changes in cholesterol (P = 0.702), triglyceride (P = 0.080), low-density lipoprotein (LDL) (P = 0.986), high-density lipoprotein (HDL) (P = 0.687) and fasting blood glucose (P = 0.614) did not differ significantly between intervention and control groups.

conclusionAlthough crocin supplements increased the serum cholesteryl ester transfer protein in patients with metabolic syndrome, this change was not significant between treatment and placebo groups.

Indexed as

Cholesteryl Ester Transfer ProteinCrocinHigh-Density Lipoprotein CholesterolLow-Density Lipoprotein CholesterolMetabolic SyndromeSaffron

Identifiers

PMID29371871
PMCPMC5774797
OpenAlexW2767339377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.